Effect of inhaled thiorphan, a neutral endopeptidase inhibitor, on the bronchodilator response to inhaled atrial natriuretic peptide (ANP)

Robert M Angus, Evelyn A Millar, George W Chalmers, Neil C Thomson

Abstract

Background – The hormone atrial natriuretic peptide (ANP) causes bronchodilation and partially protects against direct and indirect bronchial challenges. Both *in vitro* and *in vivo* studies have found that the protective effect of ANP against bronchoconstriction is enhanced by inhibition of the enzyme neutral endopeptidase (NEP). It was hypothesised that pretreatment with thiorphan, an NEP inhibitor, might enhance the bronchodilator response to inhaled ANP.

Methods – In a randomised double blind placebo controlled crossover study, six asthmatic patients (one woman) of mean (SD) age 47.3 (3.8) years and forced expiratory volume in one second (FEV₁) 1.91 (0.42) l, 55 (3.8)% predicted, were studied. All were shown at screening to have at least a 25% improvement in FEV₁ to inhaled salbutamol. On five study visits the patients received either thiorphan 1 mg (in 2 ml) followed by ANP 5 mg or placebo (saline), or placebo (saline) followed by ANP (5 mg), placebo or salbutamol 5 mg. Spirometric parameters were measured after each inhalation and thereafter for the next two hours.

Results – ANP alone caused a bronchodilator response up to 15 minutes when compared with placebo or thiorphan alone with a mean (SE) change in FEV₁ of 16.8 (8.1)% and 16.1 (6.8)% at 10 and 15 minutes from baseline, respectively. Prior inhalation of thiorphan prolonged the duration of the bronchodilator effect of ANP up to 60 minutes with a mean (SE) change in FEV₁ of 23.1 (3.4)% at 60 minutes. There was no difference in the maximum degree of bronchodilation following the administration of ANP alone compared with the combination of thiorphan and ANP. The degree and duration of the bronchodilator response produced by ANP, or the combination of the NEP inhibitor and ANP, were less than that produced by salbutamol.

Conclusions – These results confirm that, at least in part, the bronchodilator response to inhaled ANP is modulated by NEP. Analogues of ANP which are stable to NEP may have greater bronchodilator activity than ANP in the treatment of asthma.

(Thorax 1996;51:71-74)

Keywords: neutral endopeptidase inhibitor (NEP), thiorphan, atrial natriuretic peptide (ANP), bronchodilator, asthma.

Atrial natriuretic peptide (ANP), when administered by intravenous infusion to asthmatic patients, causes a similar degree of bronchodilation to that produced by infused and nebulised salbutamol.¹⁻³ ANP also protects against both direct and indirect bronchial challenges.^{4,5} It is not, however, orally bioavailable and inhalational studies thus far have shown only a modest effect on airway tone and reactivity.⁶⁻⁸

The relatively small effects of ANP when given by the inhaled route suggest that it may be being degraded within the airways. ANP is cleaved enzymatically by neutral endopeptidase (NEP); this enzyme is found in airway epithelium and it is of note that concentrations of NEP in the airways are higher than those found in the lung vasculature or parenchyma.⁹ *In vitro* we have found that the addition of phosphoramidon, whose actions include the inhibition of NEP, enhances the relaxant and protective effects of ANP on airway smooth muscle.¹⁰ *In vivo* the protective effect of ANP against histamine-induced bronchoconstriction is enhanced by pretreatment with thiorphan,¹¹ a potent inhibitor of NEP.¹² An alternative approach to harnessing the bronchodilator potential of inhaled ANP on the airway might therefore be to inhibit NEP locally and so prevent the breakdown of exogenously administered ANP.

The present study was designed to determine the effect of preinhalation of thiorphan on the bronchodilator response to inhaled ANP in asthmatic patients.

Methods

PATIENTS

Six asthmatic patients (one woman) of mean (SD) age 47.3 (3.8) years and forced expiratory volume in one second (FEV₁) of 1.91 (0.42) l, 55 (3.8)% predicted, were studied (table 1). Asthma was defined according to ATS criteria.¹³ Due to the high cost of ANP, patient numbers were limited to six, all of whom had shown an improvement in FEV₁ to inhaled salbutamol of at least 25% at a screening visit. All were taking short acting β_2 agonists and inhaled corticosteroids. Patients had to be stable for at least six weeks before entering the study and to have had no alteration in their

Department of Respiratory Medicine, Western Infirmary, Glasgow G11 6NT, UK
R M Angus
E A Millar
G W Chalmers
N C Thomson

Correspondence to:
Dr N C Thomson.

Received 7 March 1995
Returned to authors
5 June 1995
Revised version received
14 August 1995
Accepted for publication
7 September 1995

Table 1 Patient characteristics

Patient no.	Age (years)	Forced expiratory volume in one second (FEV ₁)		Therapy
		Absolute value (l)	% Predicted	
1	53	2.79	74	S,B,T
2	40	1.29	39	S,B,P
3	37	3.64	91	S,B,Salm
4	40	1.68	60	S,B
5	55	0.90	27	S,B,P
6	59	1.46	40	S,B,P
Mean (SD)	47.3 (3.8)	1.91 (0.42)	55 (3.8)	

B = inhaled beclomethasone dipropionate >1000 µg; S = inhaled salbutamol; Salm = inhaled salmeterol; P = prednisolone; T = theophylline.

regular treatment. The study had the approval of the Glasgow West ethical committee and informed written consent was obtained from each patient.

STUDY DESIGN

A randomised double blind placebo controlled study design was employed. Before each study day patients were asked to withhold short acting β_2 agonists for eight hours, long acting β_2 agonists for at least 15 hours, and theophyllines for 24 hours. Inhaled and oral corticosteroids were continued unaltered. If the FEV₁ was within 15% of the baseline on the screening day the study proceeded on that day. Patients were asked to sit and an intravenous cannula was inserted for blood sampling in the antecubital vein. Patients remained seated throughout the study while spirometric tests were performed. Before dosing, heart rate and blood pressure were measured. Blood pressure and pulse were monitored using a semiautomatic sphygmomanometer. On five separate study visits they received an initial inhalation of either thiorphan (Sigma Chemical Company, Poole, Dorset, UK), 1 mg (in 2 ml), followed by ANP 5 mg or placebo (saline), or an initial inhalation of placebo (saline) followed by ANP (5 mg) (α -human ANP 28 amino acid; UCB, Pharma, Brussels, Belgium), placebo, or salbutamol 5 mg. All inhalations were administered by a Sidestream nebuliser with a Mizer aerosol conservation device driven by a Porta-Neb compressor (Medic-Aid, Pagham, Sussex, UK). The residual volume after nebulisation was 0.6 ml. Spirometric values were measured immediately after each inhalation and then followed for two hours after the second inhalation at times 0, 5, 10, 15, 30, 60, 90, and 120 minutes. The FEV₁ (best of three) was measured using a dry wedge spirometer (Vitalograph S; Vitalograph, Buckingham, UK). Blood (20 ml) was sampled for drug and hormone levels (ANP, cyclic guanosine monophosphate (cGMP), and catecholamines) at 0, 5, 10, 15, 30, 60, 90, and 120 minutes.

HORMONE ASSAYS

ANP

Venous blood (10 ml) was collected into potassium EDTA tubes containing 1000 IU aprotinin (Bayer, Newbury, UK), stored on ice and spun within two hours. Plasma was stored at -20°C and ANP was later measured by radio-

immunoassay following pre-extraction with C18 reverse phase columns (Sep-Pak; Waters, Milford, Massachusetts, USA). Both inter-assay and intra-assay variation were $\leq 8\%$.¹⁴

cGMP

Venous blood (5 ml) was collected into lithium heparin tubes, stored on ice, and spun within two hours. Cyclic GMP was later measured by radioimmunoassay after pre-extraction of plasma onto Amprep minicolumns (Amersham International, Aylesbury, Buckinghamshire, UK) [RPN1918].¹⁵

Catecholamines

Venous blood (5 ml) was collected into lithium heparin tubes, stored on ice, and spun within two hours. Plasma adrenaline and nor-adrenaline levels were measured by reverse phase high performance chromatography and electrochemical detection was carried out after extraction from plasma using activated alumina. The coefficient of variation for this assay is $<10\%$.¹⁶

DATA ANALYSIS

Changes in FEV₁ (% change), pulse, and blood pressure were compared using analysis of variance of repeated measures and Dunnett's test for correction. This was performed on an Apple Macintosh LC personal computer using the Statview software package. A p value of <0.05 was taken as significant.

Results

Baseline FEV₁ was similar on all visits. There were no significant changes in FEV₁ following thiorphan or placebo (table 2).

ANP alone caused a significant bronchodilator response up to 15 minutes when compared with placebo or thiorphan alone (mean (SE) change in FEV₁ of 16.8 (8.1)% and 16.1 (6.8)% from baseline at 10 and 15 minutes, respectively; fig 1). Prior inhalation of thiorphan significantly prolonged the duration of the bronchodilator effect of ANP up to 60 minutes (mean (SE) change in FEV₁ of 23.1 (3.4)%). There was no difference in the maximum degree of bronchodilation following the administration of ANP alone compared with the combination of thiorphan and ANP. With both ANP and the combination of the NEP inhibitor and ANP the degree of bronchodilation was significantly less than that produced by salbutamol which was maximal at one hour (mean (SE) change in FEV₁ of 53 (10.5)% and maintained at two hours (fig 1)).

ANP and cGMP levels were significantly raised at both visits when ANP was administered (figs 2 and 3). Maximal mean (SE) levels of ANP of 13.2 (4.5) pmol/l and cGMP of 11 (1.8) pmol/l were achieved when the inhalation of ANP was preceded by placebo compared with an ANP level of 39 (13.5) pmol/l and a cGMP level of 28 (5.8) pmol/l with thiorphan pretreatment. The significantly

Table 2 Effect of inhalation of thiorphan and ANP on baseline mean (SE) forced expiratory volume in one second (FEV₁) in litres

	PP	PA	TP	TA	PS
Baseline	2.19 (0.4)	2.06 (0.4)	2.10 (0.4)	2.12 (0.4)	2.04 (0.4)
Immediately after 1st inhalation	2.03 (0.4)	2.09 (0.4)	2.02 (0.5)	2.21 (0.4)	1.97 (0.3)
Immediately after 2nd inhalation	2.16 (0.4)	2.07 (0.4)	2.26 (0.5)	2.49 (0.5)	2.45 (0.5)*

PP = placebo + placebo; PA = placebo + ANP; TP = thiorphan + placebo; TA = thiorphan + ANP; PS = placebo + salbutamol.
* $p < 0.05$ when compared with baseline.

higher ANP and cGMP levels on the thiorphan/ANP treatment days when compared with placebo/ANP lasted up to 15 and 30 minutes, respectively (figs 2 and 3). Thiorphan itself did not cause a significant change in ANP or cGMP levels. There were no significant changes in catecholamines on any visit (data not shown).

There were no measured changes in pulse or blood pressure on placebo or active treatment days after thiorphan, ANP, or the combination of ANP and thiorphan. A significant tachycardia was noted with salbutamol (data not shown).

Discussion

These results confirm our previous observation that ANP in high doses can produce a significant bronchodilator response when given by inhalation.⁸ They also demonstrate that prior inhalation of the NEP inhibitor thiorphan prolongs the bronchodilator effect of inhaled ANP in asthmatic patients. In a previous study we have found in vitro that pretreatment with the NEP inhibitor phosphoramidon enhances the ability of ANP to relax precontracted bronchial smooth muscle and also to enhance the protectant effect of ANP against methacholine-induced contraction.⁹ We have also previously found that in vivo prior inhalation with thiorphan can enhance the protectant effect of ANP against histamine-induced bronchoconstriction.¹⁰ In this study we have found that pretreatment with thiorphan allows higher levels of circulating ANP and cGMP to be attained, and that this elevation is prolonged by thiorphan. Our results would therefore confirm that airway NEP is important, at least in part, in modulating the effect of inhaled ANP in humans.

It should be noted, however, that there was only partial bronchodilation when the response to ANP was compared with that to salbutamol. In the studies of infused ANP the degree of bronchodilation was very similar.¹⁻³ Several factors may explain this. Firstly, although thiorphan is a potent inhibitor of NEP we have no direct measure of inhibition of the enzyme and it could easily be envisaged that this may only be partial, therefore affording only a degree of protection against ANP breakdown. Secondly, there is some evidence in pulmonary tissue that inactivation of ANP may occur following binding to a clearance receptor and that this effect is not inhibited by thiorphan.¹⁷ Thirdly, although ANP receptors have been demonstrated in the lungs of other species, these have not been sought in humans, and the precise site of action of the ANP in the lung is not certain. Fourthly, there are no dose response studies of the airway response to ANP by the inhalational route; practicalities of solubility, time of nebulisation, and expense limited us to the 5 mg dose administered and to the small sample size. It is possible that higher doses – perhaps given by the aerosol route – would have a larger effect. Certainly the achieved

Figure 1 Mean (SE) change in FEV₁ (%) following placebo, atrial natriuretic peptide (ANP), thiorphan, and thiorphan plus ANP and salbutamol in six asthmatic patients. PP = placebo + placebo; PA = placebo + ANP; TP = thiorphan + placebo; TA = thiorphan + ANP; PS = placebo + salbutamol. * $p < 0.05$ compared with PP and TP.

Figure 2 Mean (SE) change in plasma atrial natriuretic peptide (ANP) levels following inhalation of placebo, ANP, thiorphan, and thiorphan plus ANP and salbutamol in six asthmatic patients. PP = placebo + placebo; PA = placebo + ANP; TP = thiorphan + placebo; TA = thiorphan + ANP; PS = placebo + salbutamol. * $p < 0.05$ compared with PP and TP.

Figure 3 Mean (SE) change in plasma cyclic guanosine monophosphate (cGMP) levels following inhalation of placebo, atrial natriuretic peptide (ANP), thiorphan, and thiorphan plus ANP and salbutamol in six asthmatic patients. PP=placebo + placebo; PA=placebo + ANP; TP=thiorphan + placebo; TA=thiorphan + ANP; PS=placebo + salbutamol. * $p < 0.05$ compared with PP.

circulating levels of ANP and cGMP are considerably less than was seen in our infused studies of ANP. With higher systemic levels of ANP, however, there is a possibility of significant cardiovascular effects,³ although no such effects were noted in the present study. Similarly, there was no alteration in catecholamine levels to suggest that the bronchodilator effect was mediated indirectly due to the release of adrenaline.

It may also be of importance that, in addition to ANP, NEP cleaves various active peptides including bradykinin and tachykinins such as neurokinin A and substance P.¹⁸ Several of these mediators have bronchoconstrictor properties^{18,19} and it might be speculated that inhibition of NEP would increase local levels of these agents, potentially antagonising any bronchodilator effect of ANP and cGMP. Against this, however, is our previous observation that acute administration of the oral NEP inhibitor candoxatril does not alter bronchomotor tone or non-specific reactivity, and the observation here that thiorphan alone does not cause a fall in FEV₁.²⁰

ANP given intravenously is a potent bronchodilator, but when administered by inhalation it appears to be less effective. This study shows that ANP can cause significant bronchodilation when given by inhalation and that, at least in part, this is modulated by NEP. ANP is attractive as a possible therapeutic agent in airways disease because of its different intracellular mode of action and the potential of interactive effects with current bronchodilator therapies.²¹ At present, however, it remains that any likely clinical application of ANP in asthma would be limited to the intravenous route.

Nevertheless, there remains the prospect that it may be possible to exploit the bronchodilator effects of inhaled agents acting on the particulate guanylyl cyclase pathway; one possibility for this would be the inhalation of ANP analogues stable to the clearance of the peptide in the lung.

The authors wish to thank Ms Wendy Fallon and Ms Catherine Glen for their help with drug preparation and the blinding of the study. They also wish to thank Dr JJ Morton for his help with hormone analysis. ANP was kindly supplied by UCB Pharma.

RMA was supported by the British Lung Foundation.

- Hulks G, Jardine A, Connell JMC, Thomson NC. Bronchodilator effect of atrial natriuretic peptide in asthma. *BMJ* 1989;299:1081-2.
- Chanez P, Mann C, Bousquet J, Chabrier PE, Godard P, Braquet P, et al. Atrial natriuretic factor (ANF) is a potent bronchodilator in asthma. *J Allergy Clin Immunol* 1990; 86:321-4.
- Angus RM, MacCallum MJA, Hulks G, Thomson NC. The bronchodilator, cardiovascular and cyclic guanylyl (cGMP) response to high dose infused atrial natriuretic peptide in asthma. *Am Rev Respir Dis* 1993;147:1122-5.
- Hulks G, Jardine A, Connell JMC, Thomson NC. Influence of elevated plasma levels of atrial natriuretic factor on bronchial reactivity in asthma. *Am Rev Respir Dis* 1991; 143:778-82.
- McAlpine LG, Hulks G, Thomson NC. The effect of an intravenous infusion of atrial natriuretic factor on fog induced bronchoconstriction in patients with asthma. *Am Rev Respir Dis* 1992;146:912-5.
- Hulks G, Thomson NC. Inhaled atrial natriuretic peptide and asthmatic airways. *BMJ* 1992;304:1156.
- Angus RM, MacCallum MJA, Thomson NC. Effect of inhaled atrial natriuretic peptide on methacholine induced bronchoconstriction in asthma. *Clin Exp Allergy* 1994;24: 784-8.
- Hulks G, Thomson NC. High dose inhaled atrial natriuretic peptide is a bronchodilator in asthmatic subjects. *Eur Respir J* 1994;7:1593-7.
- Johnson AR, Ashton J, Schulz WW, Erdos EG. Neutral metalloendopeptidase in human lung tissue and cultured cells. *Am Rev Respir Dis* 1985;132:564-8.
- Angus RM, Nally JE, Young LC, McCall R, McGrath JC, Thomson NC. Modulation of the effect of atrial natriuretic peptide in human and bovine bronchi by phosphoramidon. *Clin Sci* 1994;86:291-5.
- Angus RM, Millar EA, Chalmers GW, Thomson NC. Effect of inhaled atrial natriuretic peptide and a neutral endopeptidase inhibitor on histamine-induced bronchoconstriction. *Am J Respir Crit Care Med* 1995;151:2003-5.
- Roques BP, Fournie-Zaluski MC, Soroca E, Lecomte JM, Malfroy B, Llorens C, et al. The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice. *Nature* 1980;288:286-8.
- American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. *Am Rev Respir Dis* 1987;136:225-44.
- Richards AM, Tonolo G, McIntyre GD, Leckie BJ, Robertson JIS. Radioimmunoassay for plasma alpha human natriuretic peptide: a comparison of direct and pre-extracted methods. *J Hypertension* 1987;5:227-36.
- Lyall F, Balmforth AJ, Morton JJ. Specific binding of atrial natriuretic peptide increases cyclic GMP levels in human astrocytoma cells. *J Endocrinol* 1987;117:315-21.
- Goldstein DS, Feuerstein G, Izzo JL Jr, Kopin IJ, Keiser HR. Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in man. *Life Sci* 1981;28: 467-75.
- James S, Burnstock G. Atrial and brain natriuretic peptides sharing binding sites on cultured cells from the rat trachea. *Cell Tissues Res* 1991;265:555-65.
- Erdos EG, Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. *FASEB J* 1989;3:145-51.
- Nadel JA. Neutral endopeptidase modulates neurogenic inflammation. *Eur Respir J* 1991;4:745-54.
- Angus RM, MacCallum MJA, Thomson NC. No effect on bronchomotor tone and histamine reactivity by the neutral endopeptidase inhibitor candoxatril in mild asthmatic patients. *Eur Respir J* 1994;7:1084-9.
- Nally JE, Clayton RA, Thomson NC, McGrath JC. The interaction of human atrial natriuretic peptide (ANP) with salbutamol, sodium nitroprusside and isosorbide dinitrate in human smooth muscle. *Br J Pharmacol* 1994;113:1328-32.